Dr. Yajun Xu is President of ShangPharma Investment Group, a life sciences and pharmaceutical industry investor. She is also the co-founder EpimAb Biotherapeutics, a firm which has developed a proprietary generator of molecules with antibody-like properties for immuno-oncology therapeutics, and a board member and advisor to multiple biopharmaceutical companies in the U.S. and Greater China.

Previously, Dr. Xu served as Senior Vice President of Corporate Development for ShangPharma and, prior to that, Executive Vice President of Biology and Pre-Clinical Services at ChemPartner. Prior to this, she was Director of Inflammation at Millennium Pharmaceuticals (now Takeda Pharmaceutical) and a Senior Scientist at BASF Bioresearch (now AbbVie Bioresearch Center). She received her Ph.D. in Biochemistry at Brandeis University and pursued post-doctoral training at the Harvard School of Public Health.